Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia
About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve molecular complete remission or who subsequently relapse are not cured by current chemo- or targeted therapies. Previously, the sole therapeutic option for such persons was a hematopoietic stem cell transpla...
Gespeichert in:
| Veröffentlicht in: | Blood reviews 2023-05, Vol.59, p.101042-101042, Article 101042 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101042 |
|---|---|
| container_issue | |
| container_start_page | 101042 |
| container_title | Blood reviews |
| container_volume | 59 |
| creator | Kegyes, David Jitaru, Ciprian Ghiaur, Gabriel Ciurea, Stefan Hoelzer, Dieter Tomuleasa, Ciprian Gale, Robert Peter |
| description | About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve molecular complete remission or who subsequently relapse are not cured by current chemo- or targeted therapies. Previously, the sole therapeutic option for such persons was a hematopoietic stem cell transplant. Recently, several immune therapies including monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs) have been shown safe and effective in this setting. In this manuscript, we summarize data on US FDA-approved immune therapies of advanced adult B-ALL including rituximab, blinatumomab, inotuzumab ozogamicin, tisagenlecleucel and brexucabtagene autoleucel. We consider the results of clinical trials focusing on efficacy, safety, and quality of life (QoL). Real-world evidence is presented as well. We also briefly discuss pharmacodynamics, pharmacokinetics, and pharmacoeconomics followed by risk-benefit analyses. Lastly, we present future directions of immune therapies for advanced B-ALL in adults. |
| doi_str_mv | 10.1016/j.blre.2023.101042 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2773121604</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0268960X23000036</els_id><sourcerecordid>2773121604</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-2fe98f2f054cce6ac19421392d6efe965d384868824aa4333bb5d27eee7301823</originalsourceid><addsrcrecordid>eNp9kE9v2zAMxYWhw5pm-wI7FDr24kyibNkGemmL_hkQYIe1wG6CLNOJMsnOJLlFvv1spMtxFxIg33sgf4R85WzFGZffdqvGBVwBAzEPWA4fyIIXAjIuK35GFgxkldWS_TonFzHuGGO1kOUncj5VAcCKBdE_32wyW9tvaBcGT6N2r3qD1GzRD2mLQe8PNA3Uej_2p4HtqW5Hl-htZtA5qs2YkLqD32-HxumYrKEOx9_orf5MPnbaRfzy3pfk5eH--e4pW_94_H53s86MKGTKoMO66qBjRW4MSm14nQMXNbQSp5UsWlHllawqyLXOhRBNU7RQImIpGK9ALMnVMXcfhj8jxqS8jfN1usdhjArKUnDgkuWTFI5SE4YYA3ZqH6zX4aA4UzNatVMzWjWjVUe0k-nyPX9sPLYnyz-Wk-D6KMDpy1eLQUVjsTfY2oAmqXaw_8v_C-q2ixM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2773121604</pqid></control><display><type>article</type><title>Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Kegyes, David ; Jitaru, Ciprian ; Ghiaur, Gabriel ; Ciurea, Stefan ; Hoelzer, Dieter ; Tomuleasa, Ciprian ; Gale, Robert Peter</creator><creatorcontrib>Kegyes, David ; Jitaru, Ciprian ; Ghiaur, Gabriel ; Ciurea, Stefan ; Hoelzer, Dieter ; Tomuleasa, Ciprian ; Gale, Robert Peter</creatorcontrib><description>About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve molecular complete remission or who subsequently relapse are not cured by current chemo- or targeted therapies. Previously, the sole therapeutic option for such persons was a hematopoietic stem cell transplant. Recently, several immune therapies including monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs) have been shown safe and effective in this setting. In this manuscript, we summarize data on US FDA-approved immune therapies of advanced adult B-ALL including rituximab, blinatumomab, inotuzumab ozogamicin, tisagenlecleucel and brexucabtagene autoleucel. We consider the results of clinical trials focusing on efficacy, safety, and quality of life (QoL). Real-world evidence is presented as well. We also briefly discuss pharmacodynamics, pharmacokinetics, and pharmacoeconomics followed by risk-benefit analyses. Lastly, we present future directions of immune therapies for advanced B-ALL in adults.</description><identifier>ISSN: 0268-960X</identifier><identifier>EISSN: 1532-1681</identifier><identifier>DOI: 10.1016/j.blre.2023.101042</identifier><identifier>PMID: 36732205</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Antibodies, Bispecific - adverse effects ; Antineoplastic Agents, Immunological - therapeutic use ; B-cell acute lymphoblastic leukemia ; Blinatumomab ; Brexucabtagene autoleucel ; Humans ; Immune therapy ; Immunotherapy ; Inotuzumab ozogamicin ; Inotuzumab Ozogamicin - therapeutic use ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Quality of Life ; Tisagenlecleucel</subject><ispartof>Blood reviews, 2023-05, Vol.59, p.101042-101042, Article 101042</ispartof><rights>2023</rights><rights>Copyright © 2023. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-2fe98f2f054cce6ac19421392d6efe965d384868824aa4333bb5d27eee7301823</citedby><cites>FETCH-LOGICAL-c356t-2fe98f2f054cce6ac19421392d6efe965d384868824aa4333bb5d27eee7301823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.blre.2023.101042$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36732205$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kegyes, David</creatorcontrib><creatorcontrib>Jitaru, Ciprian</creatorcontrib><creatorcontrib>Ghiaur, Gabriel</creatorcontrib><creatorcontrib>Ciurea, Stefan</creatorcontrib><creatorcontrib>Hoelzer, Dieter</creatorcontrib><creatorcontrib>Tomuleasa, Ciprian</creatorcontrib><creatorcontrib>Gale, Robert Peter</creatorcontrib><title>Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia</title><title>Blood reviews</title><addtitle>Blood Rev</addtitle><description>About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve molecular complete remission or who subsequently relapse are not cured by current chemo- or targeted therapies. Previously, the sole therapeutic option for such persons was a hematopoietic stem cell transplant. Recently, several immune therapies including monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs) have been shown safe and effective in this setting. In this manuscript, we summarize data on US FDA-approved immune therapies of advanced adult B-ALL including rituximab, blinatumomab, inotuzumab ozogamicin, tisagenlecleucel and brexucabtagene autoleucel. We consider the results of clinical trials focusing on efficacy, safety, and quality of life (QoL). Real-world evidence is presented as well. We also briefly discuss pharmacodynamics, pharmacokinetics, and pharmacoeconomics followed by risk-benefit analyses. Lastly, we present future directions of immune therapies for advanced B-ALL in adults.</description><subject>Adult</subject><subject>Antibodies, Bispecific - adverse effects</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>B-cell acute lymphoblastic leukemia</subject><subject>Blinatumomab</subject><subject>Brexucabtagene autoleucel</subject><subject>Humans</subject><subject>Immune therapy</subject><subject>Immunotherapy</subject><subject>Inotuzumab ozogamicin</subject><subject>Inotuzumab Ozogamicin - therapeutic use</subject><subject>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Quality of Life</subject><subject>Tisagenlecleucel</subject><issn>0268-960X</issn><issn>1532-1681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9v2zAMxYWhw5pm-wI7FDr24kyibNkGemmL_hkQYIe1wG6CLNOJMsnOJLlFvv1spMtxFxIg33sgf4R85WzFGZffdqvGBVwBAzEPWA4fyIIXAjIuK35GFgxkldWS_TonFzHuGGO1kOUncj5VAcCKBdE_32wyW9tvaBcGT6N2r3qD1GzRD2mLQe8PNA3Uej_2p4HtqW5Hl-htZtA5qs2YkLqD32-HxumYrKEOx9_orf5MPnbaRfzy3pfk5eH--e4pW_94_H53s86MKGTKoMO66qBjRW4MSm14nQMXNbQSp5UsWlHllawqyLXOhRBNU7RQImIpGK9ALMnVMXcfhj8jxqS8jfN1usdhjArKUnDgkuWTFI5SE4YYA3ZqH6zX4aA4UzNatVMzWjWjVUe0k-nyPX9sPLYnyz-Wk-D6KMDpy1eLQUVjsTfY2oAmqXaw_8v_C-q2ixM</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Kegyes, David</creator><creator>Jitaru, Ciprian</creator><creator>Ghiaur, Gabriel</creator><creator>Ciurea, Stefan</creator><creator>Hoelzer, Dieter</creator><creator>Tomuleasa, Ciprian</creator><creator>Gale, Robert Peter</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202305</creationdate><title>Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia</title><author>Kegyes, David ; Jitaru, Ciprian ; Ghiaur, Gabriel ; Ciurea, Stefan ; Hoelzer, Dieter ; Tomuleasa, Ciprian ; Gale, Robert Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-2fe98f2f054cce6ac19421392d6efe965d384868824aa4333bb5d27eee7301823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Antibodies, Bispecific - adverse effects</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>B-cell acute lymphoblastic leukemia</topic><topic>Blinatumomab</topic><topic>Brexucabtagene autoleucel</topic><topic>Humans</topic><topic>Immune therapy</topic><topic>Immunotherapy</topic><topic>Inotuzumab ozogamicin</topic><topic>Inotuzumab Ozogamicin - therapeutic use</topic><topic>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Quality of Life</topic><topic>Tisagenlecleucel</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kegyes, David</creatorcontrib><creatorcontrib>Jitaru, Ciprian</creatorcontrib><creatorcontrib>Ghiaur, Gabriel</creatorcontrib><creatorcontrib>Ciurea, Stefan</creatorcontrib><creatorcontrib>Hoelzer, Dieter</creatorcontrib><creatorcontrib>Tomuleasa, Ciprian</creatorcontrib><creatorcontrib>Gale, Robert Peter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kegyes, David</au><au>Jitaru, Ciprian</au><au>Ghiaur, Gabriel</au><au>Ciurea, Stefan</au><au>Hoelzer, Dieter</au><au>Tomuleasa, Ciprian</au><au>Gale, Robert Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia</atitle><jtitle>Blood reviews</jtitle><addtitle>Blood Rev</addtitle><date>2023-05</date><risdate>2023</risdate><volume>59</volume><spage>101042</spage><epage>101042</epage><pages>101042-101042</pages><artnum>101042</artnum><issn>0268-960X</issn><eissn>1532-1681</eissn><abstract>About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve molecular complete remission or who subsequently relapse are not cured by current chemo- or targeted therapies. Previously, the sole therapeutic option for such persons was a hematopoietic stem cell transplant. Recently, several immune therapies including monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs) have been shown safe and effective in this setting. In this manuscript, we summarize data on US FDA-approved immune therapies of advanced adult B-ALL including rituximab, blinatumomab, inotuzumab ozogamicin, tisagenlecleucel and brexucabtagene autoleucel. We consider the results of clinical trials focusing on efficacy, safety, and quality of life (QoL). Real-world evidence is presented as well. We also briefly discuss pharmacodynamics, pharmacokinetics, and pharmacoeconomics followed by risk-benefit analyses. Lastly, we present future directions of immune therapies for advanced B-ALL in adults.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36732205</pmid><doi>10.1016/j.blre.2023.101042</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-960X |
| ispartof | Blood reviews, 2023-05, Vol.59, p.101042-101042, Article 101042 |
| issn | 0268-960X 1532-1681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2773121604 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Antibodies, Bispecific - adverse effects Antineoplastic Agents, Immunological - therapeutic use B-cell acute lymphoblastic leukemia Blinatumomab Brexucabtagene autoleucel Humans Immune therapy Immunotherapy Inotuzumab ozogamicin Inotuzumab Ozogamicin - therapeutic use Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Quality of Life Tisagenlecleucel |
| title | Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T09%3A22%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Switching%20from%20salvage%20chemotherapy%20to%20immunotherapy%20in%20adult%20B-cell%20acute%20lymphoblastic%20leukemia&rft.jtitle=Blood%20reviews&rft.au=Kegyes,%20David&rft.date=2023-05&rft.volume=59&rft.spage=101042&rft.epage=101042&rft.pages=101042-101042&rft.artnum=101042&rft.issn=0268-960X&rft.eissn=1532-1681&rft_id=info:doi/10.1016/j.blre.2023.101042&rft_dat=%3Cproquest_cross%3E2773121604%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2773121604&rft_id=info:pmid/36732205&rft_els_id=S0268960X23000036&rfr_iscdi=true |